Abstract:Discovering new strategies for combating drug-resistant tumors becomes a worldwide challenge. Thereinto, stubborn drug-resistant tumor membrane is a leading obstacle on chemotherapy. Herein, we report a novel tumor-activatable amphipathic peptide-dendronized compound, which could form nanoaggregates in aqueous solutions, for perturbing tumor plasma/organelle membrane and reversing multidrug resistance. Distinguished from classical linear amphipathic peptide drugs for membrane disturbance, dendritic lysine-based architecture is designed as a multivalent scaffold to amplify the supramolecular interactions of cationic compound with drug-resistant tumor membrane. Moreover, arginine-rich residues as terminal groups are hopeful to generate multiple hydrogen bonding and electrostatic interactions with tumor membrane. On the other hand, antitumor molecule (doxorubicin) is devised as a hydrophobic moiety to intensify the membrane-inserting ability owing to the prominent interactions with hydrophobic domains of drug-resistant tumor membrane. As expected, these amphipathic peptide-dendronized compounds within the nanoaggregates could severely disturb both the structures and functions of tumor plasma/organelle membrane system, thereby resulting in the rapid leakage of many critical biomolecules, highly efficient apoptotic activation and antiapoptotic inhibition. This strategy on tumor membrane perturbation demonstrates a bran-new antitumor activity with high contributions to cell cycle arrest (at the S phase), strong apoptosis-inducing ability and satisfying cytotoxicity to a variety of drug-resistant tumor cell lines.

Design, synthesis and biological evaluation of novel peptides as potential agents with anti-tumor and multidrug resistance-reversing activities

Synthesis and Biological Evaluation of Novel Peptides Based on Antimicrobial Peptides As Potential Agents with Antitumor and Multidrug Resistance-Reversing Activities

Synthesis and Biological Evaluation of Novel Aliphatic Acid-Conjugated Antimicrobial Peptides As Potential Agents with Anti-Tumor, Multidrug Resistance-Reversing Activity and Enhanced Stability

Design, Synthesis and Biological Evaluation of Novel Peptides with Anti-Cancer and Drug Resistance-Reversing Activities.

Design, Synthesis, and Biological Evaluation of Novel Cholesteryl Peptides with Anticancer and Multidrug Resistance‐Reversing Activities

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Pro-apoptotic Cationic Host Defense Peptides Rich in Lysine or Arginine to Reverse Drug Resistance by Disrupting Tumor Cell Membrane.

Rational design of a new short anticancer peptide with good potential for cancer treatment

Engineering Anticancer Amphipathic Peptide-Dendronized Compounds for Highly-Efficient Plasma/Organelle Membrane Perturbation and Multidrug Resistance Reversal

Branched -helical peptides enhanced antitumor efficacy and selectivity

Aliphatic Acid-Conjugated Antimicrobial Peptides – Potential Agents with Anti-Tumor, Multidrug Resistance-Reversing Activity and Enhanced Stability

Design, Synthesis, and Antitumor Activity Study of All-Hydrocarbon-Stapled B1-Leu Peptides

Molecular and Supramolecular Engineering on Lipopeptide-Based Hole-Punching Nanotoxins to Trigger Multimodal Death of Drug-Resistant Tumors: Apoptosis, Necrosis and Autophagy

Research Progress on Peptides As Antitumor Agent

Heterochiral β-Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance

Design of an acid-activated antimicrobial peptide for tumor therapy.

Structure-Based Design of Peptides against G3BP with Cytotoxicity on Tumor Cells.

Molecular Mechanisms Of Anticancer Action And Cell Selectivity Of Short Alpha-Helical Peptides

Synthesis and in vitro anti-cancer evaluation of luteinizing hormone-releasing hormone-conjugated peptide

Heterochiral -Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance

Small peptides elicit anti-tumor effects in CT26 model through blocking PD-L1/PD-1 (TUM2P.900)